InvestorsHub Logo
Followers 1038
Posts 115110
Boards Moderated 13
Alias Born 06/10/2006

Re: None

Friday, 05/10/2024 8:11:42 AM

Friday, May 10, 2024 8:11:42 AM

Post# of 959
Analyst Peter Lawson from Barclays maintained a Buy rating on Iovance Biotherapeutics (IOVA), with a $22 price target.

All my posts on the site are to be considered opinions.

Readers determine the veracity of the posts they read and the credibility of other Users

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IOVA News